reason report
end-market fundament outlook solid
bottom line remain outperform view
premium analyt tool biopharma qa/qc continu
benefit fundament remain solid across key end-market
importantli biopharma deliv organ growth
quarter driven strong demand across geographi
outlook remain solid view guid appear
conserv revenu came roughli y/i organ
better street expect
out-performance larg driven biopharma growth
core market europ came strong china deliv y/i growth
top tough comp mid-teen growth prior year
expect revenu growth mid-singl digit opinion
conserv believ compani continu deliv
increasingli lever sticki biopharma qa/qc busi high
growth area includ biomolecul test china
growth outlook appear conserv pt expect
mid-singl digit revenu growth compar estim
believ conserv given organ growth
reach see unexpect headwind biopharma
china end-market two biggest driver
drive bulk growth trend involv increas test demand
biomolecul increas global prescript drug
continu drive demand qa/qc column also expect instrument
sale continu improv led lc tandem mass spec system
ms technolog continu expand food biopharma
applic also help drive addit growth biopharma
end market expect mid-singl digit growth biopharma could
see upsid estim reiter op rate increas
pt
tax reform could creat opportun due tax
reform tax rate expect increas
provid signific extra cash balanc sheet
importantli tax reform make invest environ us
much attract open potenti opportun
howev compani indic despit infus cash
hand transform invest environ
strategi remain wait right opportun
high roi
y/i quarter tough comp well
suggest still room growth china india rebound
expect qa/qc column continu see demand
increas test gener acquiti europ strong well
compani inform leerink partner llc research
revenu mm ep present ex-amort one-tim charg
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
pleas refer page import disclosur price chart analyst certif
due pharma research expect continu growth
given new outlook tax reform revenu ep
updat previous
rate water share outperform rate price target
view water posit believ growth biopharma end-market like
continu strengthen wat alreadi establish presenc biopharma qa/qc lab
biomolecul continu becom increasingli larger part poveral drug volum
world-wide continu garner premium price lc liquid chromatographi
market given best-in-class uplc system mass spec attach rate highest
industri china continu deliv double-digit growth driven demand pharma food
environmental/industri test lab underli strength recur revenu
base almost wat revenu remain sticki biopharma qa/qc lab gener
amen chang
limit exposur academ fund world-wide less exposur
direct nih fund us believ short-term concern around stock misplac
given minim exposur academ govern revenu biopharma qa/
qc lab account revenu come lc busi
believ wat core biopharma qa/qc lab continu see robust growth back
biotherapeut emerg market includ china india remain strong china
believ experienc surg instrument sale driven chines fda attempt improv
overal profil chines biopharma industri result instrument upgrad lab
china constitut sale like grow higher china continu post
double-digit growth near team deriv revenu intern
asia suggest number continu grow come year solidifi
presenc intern compani
share current trade ev/ebitda consensu estim slightli
tool averag believ could higher given premium natur
mass spec product line-up continu growth biopharma increasingli
biotherapeut enter qa/qc lab drive increas util sale even higher
uniqu differenti uplc platform continu gain market share back high
attach rate deriv price target appli premium averag
ev/ebitda multipl compris life scienc peer group
primari risk price target includ
biopharma declin pose greatest risk wat revenu slowdown
biopharmaceut fund number factor includ chang regul fda
approv process directli impact biopharma biotech compani
polit risk pose threat biopharma drug sale result sharp reduct
 spend current level revenu deriv biopharma
reduct expens biopharma like impact compani
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim signific academ exposur revenu
ww nih exposur less revenu nevertheless slowdown academ
spend could headwind plan margin expans restrict global
budget could result shift focu strategi growth could increas oper
risk declin government spend could risk downsid forecast growth
well
emerg market pose signific risk wat revenu sudden
macroeconom impact china lead declin fund could impact advers
china repres compani revenu current grow mid-teen
china chang regul lead restrict oper china foreign compani
like impact compani sale significantli
high attach rate integr part busi model disrupt could
impact revenu impact abil maintain high attach rate lc
system due chang technolog competit chang market competitor offer
superior product compar uplc increas competitor lc space could impact
water market share disrupt market model consum
fda regul remain paramount affect adopt rate clinic
diagnost tool clinic diagnost remain major growth area futur
chang regul restrict use mass spectromet clinic diagnost
laboratori could also sever affect compani restrict could affect growth adopt
rate certain tool regul would also increas cost complianc test purpos
would result declin estim
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report leerink partner estim
mid high
mid high
mid
launch discoveri dsc ta instrument
launch bio-tof instrument
compani report leerink partner estim
water thermal analysi ta divis launch new line instrument know
discoveri seri custom like delay purchas anticip
latest disocveri dsc place order benefit ta growth
quarter expect growth continu rest year
water continu drive premium acquiti uplc market
acquiti arc provid easili switch uplc hplc method
water recogn time valid medthod uplc cumbersom
flexibl must exist user switch uplc hplc mode vice
versa need
bio-tof introduc investor day meet help address
long term risk pose progress competitor mass spec
lc enter wat biopharma qa/qc stronghold take share
tmo orbitrap technolog associ dionex lc continu
inch toward biopharma qa/qc lab bio-tof introduc order
ward comeptitor
